Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | PTAFR | P25105 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20856166 | 1.00 | GID4 (0.63) | GID4KDM4ETDP1MAPK1MAPK14 | |
| SCHEMBL16202228 | 0.88 | GID4 (0.53) | GID4KDM4ETDP1MAPK1MAPK14 | |
| SCHEMBL7453365 | 0.81 | GID4 (0.64) | GID4KDM4EMAPK1MAPK14KMT2A | |
| SCHEMBL7324670 | 0.78 | GID4 (0.72) | GID4MAPK1MAPK14KMT2A | |
| SCHEMBL13444088 | 0.78 | GID4 (0.72) | GID4MAPK1MAPK14KMT2A | |
| SCHEMBL20856099 | 0.77 | GID4 (0.58) | GID4MAPK1MAPK14KMT2AMEN1 | |
| SCHEMBL20863607 | 0.77 | GID4 (1.00) | GID4MAPK1MAPK14KMT2AMEN1 | |
| SCHEMBL13343312 | 0.76 | MAPT (0.55) | MAPK1NPC1 | |
| SCHEMBL12634337 | 0.75 | GID4 (0.53) | GID4KDM4EKMT2AMEN1NPC1 | |
| SCHEMBL395087 | 0.74 | GID4 (0.62) | GID4MAPK1MAPK14KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564674-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3276349-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140323336-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8846320-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846320-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2444806-B1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MED SYST INC (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2444806-A2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444807-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2442107-A2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | Ventana Medical Systems, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | GID4 2427/4885KDM4E 3532/4885TDP1 3371/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | GID4 2122/4885KDM4E 3907/4885TDP1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.